References
1. Kaplan AP, Greaves MW.
Angioedema. J Am Acad Dermatol. 2005;53(3):373-388.
2. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and
approach to treatment for angioedema: consensus report from the
Hereditary Angioedema International Working Group. Allergy.2014;69(5):602-616.
3. Sala-Cunill A, Guilarte M. The role of mast cells mediators in
angioedema without wheals. Curr Treat Options Allergy.2015;2(4):294-306.
4. Giavina-Bianchi P, Aun MV, Motta AA, Kalil J, Castells M.
Classification of angioedema by endotypes. Clin Exp Allergy.2015;45(6):1142-1143.
5. Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M.
Positive response to omalizumab in patients with acquired idiopathic
nonhistaminergic angioedema. Ann Allergy Asthma Immunol.2015;114(5):418-419.
6. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO
guideline for the definition, classification, diagnosis and management
of urticaria. Allergy Eur J Allergy Clin Immunol.2018;73(7):1393-1414.
7. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in
chronic spontaneous urticaria. A GA2LEN task force report1.Allergy Eur J Allergy Clin Immunol. 2011;66(3):317-330.
8. Sabaté-Brescó M, Rodriguez-Garijo N, Azofra J, et al. A Comparative
Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory
Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic
Histaminergic Angioedema. J Allergy Clin Immunol Pract.2021;9(6):2284-2292.
9. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic
spontaneous urticaria is substantial: real-world evidence from
ASSURE-CSU. Allergy Eur J Allergy Clin Immunol.2017;72(12):2005-2016.
10. Weller K, Groffik A, Magerl M, et al. Development and construct
validation of the angioedema quality of life questionnaire.Allergy Eur J Allergy Clin Immunol. 2012;67(10):1289-1298.
11. Nordenfelt P, Nilsson M, Lindfors A, Wahlgren CF, Björkander J.
Health-related quality of life in relation to disease activity in adults
with hereditary angioedema in Sweden. Allergy Asthma Proc.2017;38(6):447-455.
12. Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of
hereditary angioedema: findings from a patient survey in the United
States. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
13. Caballero T, Prior N. Burden of illness and quality-of-life measures
in angioedema conditions. Immunol Allergy Clin N Am.2017;37(3):597-616.
14. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting edge:
biomarkers for chronic spontaneous urticaria. J Immunol Res.2018;2018:1-12.
15. Kolkhir P, André F, Church MK, Maurer M, Metz M. Potential blood
biomarkers in chronic spontaneous urticaria. Clin Exp Allergy.2016;47(1):19-36.
16. Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P.
Biomarkers in chronic spontaneous urticaria: current targets and
clinical implications. J Asthma Allergy. 2019;12:285-295.
17. Weller K, Groffik A, Magerl M, et al. Development, validation, and
initial results of the angioedema activity score. Allergy Eur J
Allergy Clin Immunol. 2013;68(9):1185-1192.
18. Stull D, McBride D, Tian H, et al. Analysis of disease activity
categories in chronic spontaneous/idiopathic urticaria. Br J
Dermatol. 2017;177(4):1093-1101.
19. Sussman G, Abuzakouk M, Bérard F, et al. Angioedema in chronic
spontaneous urticaria is underdiagnosed and has a substantial impact:
analyses from ASSURE-CSU. Allergy Eur J Allergy Clin Immunol.2018;73(8):1724-1734.
20. Balañá M, Valero A, Arnau AG, Ferrer M, Jauregui I, Ballesteros C.
Validation of the Spanish version of the urticaria activity score (Uas)
and its use over one week (Uas7). Value Health. 2015;18(7):A426.
21. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for
chronic spontaneous urticaria. N Engl J Med.2019;381(14):1321-1332.
22. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of
chronic idiopathic or spontaneous urticaria. N Engl J Med.2013;368(10):924-935.
23. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of
disability in different urticarial conditions. Br J Dermatol.1999;140(4):667-671.
24. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in
patients with chronic urticaria is differentially impaired and
determined by psychiatric comorbidity. Br J Dermatol.2006;154(2):294-298.
25. Ue AP, Souza PK, Rotta O, Wde JF, Lima AR, Sabbag DS. Quality of
life assessment in patients with chronic urticaria. An Bras
Dermatol. 2011;86(5):879-904.
26. Cavariani Silvares MR, Parise Fortes MR, Miot HA. Qualidade de vida
em urticária crônica: inquérito em ambulatório público universitário,
Botucatu (Brasil). Rev Assoc Med Bras. 2011;57(5):577-582.
27. Choi WS, Lim ES, Ban GY, et al. Disease-specific impairment of the
quality of life in adult patients with chronic spontaneous urticaria.Korean J Intern Med. 2018;33(1):185-192.
28. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA.
Positive impact of omalizumab on angioedema and quality of life in
patients with refractory chronic idiopathic/spontaneous urticaria:
analyses according to the presence or absence of angioedema. J Eur
Acad Dermatology Venereol. 2017;31(6):1056-1063.
29. Oles-Krykowska A, Badura-Brzoza K, Brzoza Z. Does angioedema
influence the quality of life in patients with chronic spontaneous
urticaria? Ann Allergy Asthma Immunol. 2019;122(5):539-541.
30. Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is
linked to disease activity, impact, and response to treatment in
patients with chronic spontaneous urticaria. Allergy Eur J Allergy
Clin Immunol. 2018;73(4):940-948.
31. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation
potential in chronic spontaneous urticaria. Allergy Eur J Allergy
Clin Immunol. 2011;66(3):428-433.
32. Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and
specific autoantigen of IgE in patients with chronic spontaneous
urticaria. J Allergy Clin Immunol. 2018;142(3):876-882.
33. Grattan CEH, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in
chronic ordinary urticaria and healthy controls: diurnal variation,
influence of loratadine and prednisolone and relationship to disease
activity. Clin Exp Allergy. 2003;33(3):337-341.
34. Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic
spontaneous urticaria, is associated with high disease activity,
autoimmunity, and poor response to treatment. J Allergy Clin
Immunol Pract. 2020;8(1):318-325.
35. Jauregui I, Gimenez-Arnau A, Bartra J, et al. Psychometric
properties of the Spanish version of the once-daily Urticaria Activity
Score (UAS) in patients with chronic spontaneous urticaria managed in
clinical practice (the EVALUAS study). Health Qual Life Outcomes.2019;17(1):1-9.